Compare BioNano Genomics Inc (BNGO) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs NEOS S&P 500 High Income ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while NEOS S&P 500 High Income ETF trades at $53.7. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SPYI | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.92 | $54.07 |
52-Week Low | $1.09 | $47.98 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
SPYI trades at $53.37, down 0.61% on the day, with a bullish technical signal supported by moving averages. The NEOS S&P 500 High Income ETF has surpassed $10 billion in assets under management, driven by strong investor demand for its monthly income strategy. Recent dividend payments of $0.52-$0.54 demonstrate consistent distribution capabilities, while technical indicators show support at $53 and resistance at $54.
The ETF's covered-call strategy provides high monthly income with partial upside participation, making it attractive for income-focused investors. However, the 0.68% expense ratio and potential return of capital distributions present cost considerations. Market volatility benefits the options strategy, though competition with JEPI and other income ETFs remains a key factor.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
